Robert M. Sharkey
ORCID: 0000-0003-1408-0905Also affiliated with Gilead Sciences (United States), Immunomedics (Germany)
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 3 papers. Top paper: “Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial”.
Jennifer R. Diamond, Linda T. Vahdat, Sara M. Tolaney, Dejan Juric, Joyce O’Shaughnessy +11 more
Malik Juweid, Robert M. Sharkey, Thomas M. Behr, David M. Goldenberg, Robert M. Dunn
Robert M. Sharkey, David M. Goldenberg